ARTIKEL: Exenatide: pharmacokinetics, clinical use, and future directions

​Drs. Knop, Brønden and Vilsbøll of Center from Diabetes Research provide a review of the first-in-class GLP-1 receptor agonist exenatide, which was initially approved in 2005, and is available in twice-daily and once-weekly formulations. Existing data from studies in patients with type 2 diabetes and a range of other conditions are reviewed and ongoing investigations are summarised